Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans

[cafead]

via A path forward for Merck & Co.’s struggling HIV strategy has opened up, with the FDA releasing a nine-month clinical hold on trials of the Big Pharma’s drug islatravir as long as low doses are used. However, the company has also decided to ditch its plans to explore the drug as a preventive treatment.

article source